K9 oxycodone 30mg ( k9 30s )
How k9 30s look like
Imprint K 9
Strength 30 mg
Size 6.00 mm
Drug Class Narcotic analgesics
Pregnancy Category N – Not classified
CSA Schedule 2 – High potential for abuse
Labeler / Supplier KVK Tech Inc.
National Drug Code (NDC) 10702-0009
Inactive Ingredients lactose monohydrate, corn starch, microcrystalline cellulose, silicon dioxide, sodium starch glycolate type A potato, stearic acid, FD&C Blue No. 2
Indications K9 oxycodone 30mg
Moderate to severe pain; extended release product should be used for patients requiring around-the-clock management of chronic pain
Action K9 oxycodone 30mg
Binds to opiate receptors in the CNS. Alters the perception of and response to painful stimuli, while producing generalized CNS depression. Therapeutic Effects: Decreased pain.
Absorption:Well absorbed from the GI tract.
Distribution:Widely distributed. Crosses the placenta; enters breast milk.
Protein Binding: 38– 45%.
Metabolism and Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme.
Half-life: 2– 3 hr
Contraindicated in: Hypersensitivity; Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance or hypersensitivity; Significant respiratory depression; Paralytic ileus; Acute or severe bronchial asthma; Acute,
mild, intermittent, or postoperative pain (extended-release).
Use Cautiously in: Head trauma;qintracranial pressure; Severe renal or hepatic disease; Hypothyroidism; Adrenal insufficiency; Alcoholism; Seizure disorders; Undiagnosed abdominal pain; Prostatic hyperplasia; Difficulty swallowing or GI disorders
that may predispose patient to obstruction (qrisk for GI obstruction); OB: Avoid chronic use; weigh maternal benefit against fetal risks; Lactation:Lactation; Geri: Elderly or debilitated patients (initial doseprecommended).
side effets K9 oxycodone 30mg
Learn about the reported side effects, related class drugs
Adverse Reactions/Side Effects
CNS:confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams. EENT: blurred vision, diplopia, miosis. Resp: RESPIRATORY DEPRESSION. CV: orthostatic hypotension. GI:constipation, dry mouth,
choking, GI obstruction, nausea, vomiting. GU: urinary retention. Derm: flushing, sweating.Misc: physical dependence, psychological dependence, tolerance
Drug-Drug: Use with caution in patients receiving MAO inhibitors (may result in unpredictable reactions—pinitial dose of K9 oxycodone 30mg to 25% of usual dose). Additive CNS depression with alcohol, antihistamines, and sedative/hypnotics.
Administration of partial-antagonist opioid analgesics may
precipitate withdrawal in physically dependent patients. Nalbuphine, buprenorphine, or pentazocine maypanalgesia. Potent CYP3A4 inhibitors including erythromycin, ketoconazole, itraconazole, voriconazole, or ritonavir may qlevels. Potent CYP3A4 inducersincludingrifampin,carbamazepine, and phenytoinmayplevels.